MedTrace Logo

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

NCT07070466 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-06

No results posted yet for this study

Summary

This is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.

Conditions

  • Stomach Cancer Stage IV
  • Esophagus Cancer
  • Stomach Cancer

Interventions

DRUG

Ivonescimab

Humanized immunoglobulin G1 monoclonal antibody

DRUG

5-Fluorouracil

Nucleoside metabolic inhibitor

DRUG

Oxaliplatin

Platinum-based drug and organoplatinum complex

DRUG

Leucovorin

5-formyl derivative of tetrahydrofolic acid

Sponsors & Collaborators

  • Summit Therapeutics

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Samuel Klempner, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-10
Primary Completion
2026-12-01
Completion
2028-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07070466 on ClinicalTrials.gov